title: Breast cancer and pregnancy: how safe is trastuzumab?
abstract: BACKGROUND
  A 29-year-old woman was diagnosed with lymph-node-positive, steroid-hormone-receptor-negative and HER2/neu-positive breast cancer. She underwent surgery followed by cyclophosphamide, epirubicin, and 5-fluorouracil chemotherapy, and received radiotherapy followed by trastuzumab therapy for 1 year. During the tenth month of trastuzumab therapy, the patient reported a missed period and had a positive pregnancy test.
  
  
  METHODS
  Physical examination, pregnancy test, echocardiography.
  
  
  METHODS
  Unintended pregnancy during adjuvant trastuzumab therapy.
  
  
  RESULTS
  Cessation of trastuzumab and close monitoring of mother and fetus during pregnancy.
authors.affiliation: Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy.
authors.forename: Hatem A
authors.initials: HA
authors.lastname: Azim
authors.forename: Fedro A
authors.initials: FA
authors.lastname: Peccatori
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Liptrott
authors.forename: Chiara
authors.initials: C
authors.lastname: Catania
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis* / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide; D015251:Epirubicin; D005472:Fluorouracil; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab